The current status of immunobased therapies for metastatic renal-cell carcinoma.

Immunotargets Ther · 2017 · PMC5723125 · PMID 29255699

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP =0.09so close (0.05 < p ≤ 0.1)

While progression-free survival was comparable in both groups of this study, patients that received cyclophosphamide had an increase in overall survival, although this did not reach statistical significance (23.5 months vs 14.8 months, P =0.09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.